Approval · Notice of Compliance 18901 · 2017
INVOKANA: Notice of Compliance 18901
Issued January 20, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18901
- Date
- January 20, 2017
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph to include increased risk on bone fractures with the use of canagliflozin in response to an advisement letter
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INVOKANA | Not yet assigned | — |
Medicinal ingredients
- CANAGLIFLOZIN 100 MG per MG
- CANAGLIFLOZIN 300 MG per MG